Olmesartan medoxomil decreases serum cystatin C levels in hypertensive patients, suggesting that this agent can counteract renal damage, according to a study published in Blood Pressure (2009; published online ahead of print). The drug also reduces left ventricular hypertrophy.

The study, by researchers at Duzce University in Duzce, Turkey, included 44 patients with newly diagnosed hypertension.

They were treated with olmesartan medoxomil 20 mg/day and had six months of follow-up.

Continue Reading